Boston Scientific's product portfolio continues to be a key driver of its success, with particular attention focused on its Watchman FLX Left Atrial Appendage Closure (LAAC) device. The OPTION ...

Boston Scientific's product portfolio continues to be a key driver of its success, with particular attention focused on its Watchman FLX Left Atrial Appendage Closure (LAAC) device. The OPTION ...

It is the first device to offer a non-pharmacologic alternative ... The next generation WATCHMAN FLX and FLX Pro are strongly capturing theglobal market In the third quarter of 2024, WATCHMAN ...

The trial data provided clinical evidence indicating that LAAC with the WATCHMAN FLX device is safe and superior to oral anticoagulation (OAC) therapy for reducing the risk of long-term bleeding ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s Electrophysiology (EP) ...

WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) device, enhancing stroke prevention options for patients with non-valvular ...

The company's Watchman FLX Left Atrial Appendage Closure (LAAC) device has shown promising results in clinical trials. The OPTION trial demonstrated superior bleeding risk reduction compared to ...

In addition to acquisitions, Boston Scientific continues to invest in its product pipeline. The company's Watchman FLX Left Atrial Appendage Closure (LAAC) device has shown promising results in ...